TISIDB

Summary
Symbol	ODC1
Name	ornithine decarboxylase 1
Aliases	Ornithine decarboxylase
Chromosomal Location	2p25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF02784 Pyridoxal-dependent decarboxylase PF00278 Pyridoxal-dependent decarboxylase
Function	Catalyzes the first and rate-limiting step of polyamine biosynthesis that converts ornithine into putrescine, which is the precursor for the polyamines, spermidine and spermine. Polyamines are essential for cell proliferation and are implicated in cellular processes, ranging from DNA replication to apoptosis.

> Gene Ontology [ TOP ]
Biological Process	GO:0001655 urogenital system development GO:0001822 kidney development GO:0006520 cellular amino acid metabolic process GO:0006521 regulation of cellular amino acid metabolic process GO:0006576 cellular biogenic amine metabolic process GO:0006591 ornithine metabolic process GO:0006595 polyamine metabolic process GO:0006596 polyamine biosynthetic process GO:0009308 amine metabolic process GO:0009309 amine biosynthetic process GO:0009445 putrescine metabolic process GO:0009446 putrescine biosynthetic process GO:0009615 response to virus GO:0009894 regulation of catabolic process GO:0010565 regulation of cellular ketone metabolic process GO:0033238 regulation of cellular amine metabolic process GO:0033387 putrescine biosynthetic process from ornithine GO:0042176 regulation of protein catabolic process GO:0042180 cellular ketone metabolic process GO:0042401 cellular biogenic amine biosynthetic process GO:0044106 cellular amine metabolic process GO:0072001 renal system development
Molecular Function	GO:0004586 ornithine decarboxylase activity GO:0016829 lyase activity GO:0016830 carbon-carbon lyase activity GO:0016831 carboxy-lyase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00330 Arginine and proline metabolism hsa00480 Glutathione metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-1430728: Metabolism R-HSA-71291: Metabolism of amino acids and derivatives R-HSA-351202: Metabolism of polyamines R-HSA-350562: Regulation of ornithine decarboxylase (ODC)

Summary
Symbol	ODC1
Name	ornithine decarboxylase 1
Aliases	Ornithine decarboxylase
Chromosomal Location	2p25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ODC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between ODC1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24778323	Lymphoma; Melanoma; Colon Carcinoma; Breast Carcinoma	Inhibit immunity (infiltration)	A polyamine-blocking therapy (PBT) that combines the well-characterized ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) with AMXT 1501, a novel inhibitor of the polyamine transport system, blocked tumor growth in immunocompetent mice but not in athymic nude mice lacking T cells\j Analysis of CD45(+) tumor immune infiltrates revealed that PBT decreased levels of Gr-1(+)CD11b(+) myeloid suppressor cells and increased CD3(+) T cells.

Summary
Symbol	ODC1
Name	ornithine decarboxylase 1
Aliases	Ornithine decarboxylase
Chromosomal Location	2p25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ODC1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.51	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ODC1
Name	ornithine decarboxylase 1
Aliases	Ornithine decarboxylase
Chromosomal Location	2p25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ODC1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.607	0.216
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.071	0.978
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-1.108	0.586
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.338	0.326
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.051	0.976
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.705	0.758
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.068	0.884
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.209	0.91
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.483	0.801
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.545	0.761
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.264	0.92
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.001	0.993

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ODC1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ODC1
Name	ornithine decarboxylase 1
Aliases	Ornithine decarboxylase
Chromosomal Location	2p25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ODC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ODC1
Name	ornithine decarboxylase 1
Aliases	Ornithine decarboxylase
Chromosomal Location	2p25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ODC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ODC1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ODC1
Name	ornithine decarboxylase 1
Aliases	Ornithine decarboxylase
Chromosomal Location	2p25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ODC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ODC1
Name	ornithine decarboxylase 1
Aliases	Ornithine decarboxylase
Chromosomal Location	2p25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ODC1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ODC1
Name	ornithine decarboxylase 1
Aliases	Ornithine decarboxylase
Chromosomal Location	2p25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ODC1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ODC1
Name	ornithine decarboxylase 1
Aliases	Ornithine decarboxylase
Chromosomal Location	2p25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ODC1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting ODC1.

ID	Name	Drug Type	Targets	#Targets
DB00114	Pyridoxal Phosphate	Small Molecule	AADAT, ABAT, AGXT, AGXT2, ALAS1, ALAS2, AZIN2, BCAT1, BCAT2, CBS, ......	54
DB00127	Spermine	Small Molecule	ADRB1, ADRB2, CASR, ODC1, SMOX, SMS	6
DB01917	Putrescine	Small Molecule	ADRB1, ADRB2, AMD1, ODC1	4
DB02209	Pyridoxine phosphate	Small Molecule	ODC1	1
DB02824	N-Pyridoxyl-Glycine-5-Monophosphate	Small Molecule	ODC1, SHMT1	2
DB03856	L-Eflornithine	Small Molecule	ODC1	1
DB04083	N'-Pyridoxyl-Lysine-5'-Monophosphate	Small Molecule	AGXT, CCBL1, ODC1, PYGM	4
DB04263	Geneticin	Small Molecule	ODC1	1
DB06243	Eflornithine	Small Molecule	ODC1	1

Browse ODC1